MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-25-2025
Becton, Dickinson and Company Accounts Receivables 2011-2026 | BDX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.99 B | 3.03 B | 2.53 B | 2.19 B | 2.35 B | 2.4 B | 2.34 B | 2.32 B | 1.74 B | 1.62 B | 1.62 B | 1.19 B | 1.24 B | 1.25 B | 1.23 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.03 B | 1.19 B | 2 B |
Quarterly Accounts Receivables Becton, Dickinson and Company
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.94 B | 3.03 B | 2.64 B | 2.6 B | 2.56 B | 2.27 B | 2.41 B | 2.41 B | 2.28 B | 2.19 B | - | 2.3 B | 2.18 B | 2.5 B | 2.08 B | 2.5 B | 2.37 B | 2.4 B | 2.4 B | 2.4 B | 2.07 B | 2.34 B | 2.34 B | 2.34 B | 2.22 B | 2.32 B | 2.32 B | 2.32 B | 2 B | 1.74 B | 1.74 B | 1.74 B | 1.52 B | 1.62 B | 1.62 B | 1.57 B | 1.51 B | 1.62 B | 1.64 B | 1.62 B | 1.03 B | 1.19 B | 1.19 B | 1.19 B | 1.11 B | 1.24 B | 1.24 B | 1.24 B | 1.17 B | 1.25 B | 1.25 B | 1.25 B | 1.14 B | 1.23 B | 1.23 B | 1.23 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.03 B | 1.03 B | 1.89 B |
Accounts Receivables of other stocks in the Medical instruments industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
23 K | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
1.54 B | $ 21.07 | 1.81 % | $ 10.7 B | USA |
 |
ICU Medical
ICUI
|
183 M | $ 151.86 | 0.14 % | $ 3.7 B | USA |
 |
iRhythm Technologies
IRTC
|
79.9 M | $ 180.4 | -4.68 % | $ 5.63 B | USA |
 |
Repro Med Systems
KRMD
|
4.05 M | $ 5.67 | -2.41 % | $ 259 M | USA |
 |
Masimo Corporation
MASI
|
141 M | $ 140.04 | 1.54 % | $ 7.46 B | USA |
 |
Merit Medical Systems
MMSI
|
190 M | $ 86.37 | -7.31 % | $ 5.03 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
7.24 M | $ 8.03 | -1.95 % | $ 162 M | USA |
 |
Predictive Oncology
POAI
|
746 K | $ 6.83 | 1.08 % | $ 37.2 M | USA |
 |
AtriCure
ATRC
|
60.3 M | $ 41.66 | -1.76 % | $ 1.96 B | USA |
 |
electroCore
ECOR
|
717 K | $ 5.62 | 11.73 % | $ 31 K | USA |
 |
Haemonetics Corporation
HAE
|
203 M | $ 82.2 | -2.19 % | $ 4.14 B | USA |
 |
AngioDynamics
ANGO
|
42.9 M | $ 9.97 | -0.8 % | $ 407 M | USA |
 |
Harvard Bioscience
HBIO
|
16.1 M | $ 0.64 | -1.79 % | $ 27.1 M | USA |
 |
The Cooper Companies
COO
|
829 M | $ 83.71 | 0.69 % | $ 16.7 B | USA |
 |
LeMaitre Vascular
LMAT
|
30.1 M | $ 84.83 | -0.25 % | $ 1.9 B | USA |
 |
Glaukos Corporation
GKOS
|
39.8 M | $ 113.09 | -0.93 % | $ 5.48 B | USA |
 |
InfuSystem Holdings
INFU
|
16.9 M | $ 8.61 | -4.01 % | $ 178 M | USA |
 |
Isoray
ISR
|
116 K | - | 0.03 % | $ 108 M | USA |
 |
Nephros
NEPH
|
1.5 M | $ 4.89 | -2.5 % | $ 50.8 M | USA |
 |
Utah Medical Products
UTMD
|
3.39 M | $ 59.83 | 1.87 % | $ 217 M | USA |
 |
Intuitive Surgical
ISRG
|
1.23 B | $ 587.18 | 0.36 % | $ 209 B | USA |
 |
Microbot Medical
MBOT
|
159 K | $ 2.08 | -5.02 % | $ 21.2 M |  Israel |
 |
Milestone Scientific
MLSS
|
475 K | $ 0.3 | 1.23 % | $ 23.9 M | USA |
 |
NeuroMetrix
NURO
|
193 K | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
363 M | $ 23.57 | -0.23 % | $ 4.06 B | USA |
 |
OraSure Technologies
OSUR
|
23.8 M | $ 2.63 | -1.13 % | $ 196 M | USA |
 |
Pro-Dex
PDEX
|
16.4 M | $ 41.51 | 0.51 % | $ 136 M | USA |
 |
Pulse Biosciences
PLSE
|
61 K | $ 14.63 | -0.61 % | $ 703 M | USA |
 |
Repligen Corporation
RGEN
|
124 M | $ 166.85 | 0.26 % | $ 9.3 M | USA |
 |
ResMed
RMD
|
576 M | $ 252.15 | 0.49 % | $ 36.8 B | USA |
 |
BioLife Solutions
BLFS
|
9.17 M | $ 24.8 | -0.6 % | $ 1.14 B | USA |
 |
STERIS plc
STE
|
1.04 B | $ 258.0 | -1.03 % | $ 25.4 B | USA |
 |
Stereotaxis
STXS
|
3.82 M | $ 2.53 | -2.13 % | $ 204 M | USA |
 |
Retractable Technologies
RVP
|
7.79 M | $ 0.76 | -2.53 % | $ 22.8 M | USA |
 |
STAAR Surgical Company
STAA
|
77.9 M | $ 22.06 | -1.96 % | $ 1.08 B | USA |
 |
Teleflex Incorporated
TFX
|
459 M | $ 112.75 | 2.49 % | $ 5.28 B | USA |
 |
West Pharmaceutical Services
WST
|
552 M | $ 275.51 | 0.1 % | $ 20.1 B | USA |